13F filer · CIK 1791468
CHI Advisors LLC
NEW YORK, NY · filing since Q3 2019 · last filing Nov 13, 2023
Reported value
$252.3M
$-77.3M vs prior
Positions
28
New / sold out
5 / 3
Added / reduced
9 / 8
Turnover
13.1%
buys $38.2M · sells $62.0M
Top-10 weight
81.3%
Biggest buys vs Q2 2023
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | ORCHARD THERAPEUTICS PLC | +11,559,916 | +1529.6% | +$13.2M |
| New | MINERALYS THERAPEUTICS INC | +568,379 | – | +$5.4M |
| New | BLUEPRINT MEDICINES CORP | +92,888 | – | +$4.7M |
| Added | ULTRAGENYX PHARMACEUTICAL IN | +130,000 | +152.9% | +$4.6M |
| New | MOONLAKE IMMUNOTHERAPEUTICS | +60,000 | – | +$3.4M |
| New | SAGIMET BIOSCIENCES INC | +348,842 | – | +$3.1M |
| Added | SYROS PHARMACEUTICALS INC | +531,914 | +69.3% | +$2.1M |
| Added | 2SEVENTY BIO INC | +150,000 | +17.6% | +$588.0K |
| Added | INOZYME PHARMA INC | +75,000 | +6.3% | +$315.0K |
| Added | FREELINE THERAPEUTICS HLDGS | +64,988 | +300.0% | +$279.4K |
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q2 2023
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | VECTIVBIO HLDG AG | -2,782,756 | -100.0% | $-46.9M |
| Reduced | DISC MEDICINE INC | -100,139 | -80.0% | $-4.7M |
| Reduced | ACELYRIN INC | -400,816 | -15.0% | $-4.1M |
| Reduced | DIREXION SHS ETF TR | -100,000 | -30.8% | $-2.1M |
| Reduced | PLIANT THERAPEUTICS INC | -102,818 | -3.3% | $-1.8M |
| Sold out | HOOKIPA PHARMA INC | -788,740 | -100.0% | $-694.1K |
| Reduced | RALLYBIO CORP | -152,040 | -28.0% | $-512.4K |
| Sold out | CORVUS PHARMACEUTICALS INC | -200,000 | -100.0% | $-458.0K |
| Reduced | REPARE THERAPEUTICS INC | -32,060 | -1.1% | $-387.3K |
| Reduced | PRECISION BIOSCIENCES INC | -996,928 | -62.2% | $-340.3K |
1 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2023
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | PLIANT THERAPEUTICS INCCOM | 3,014,199 | $52.3M | 20.72% |
| 2 | REPARE THERAPEUTICS INCCOM | 2,966,674 | $35.8M | 14.20% |
| 3 | CULLINAN ONCOLOGY INCCOM | 3,414,189 | $30.9M | 12.25% |
| 4 | ACELYRIN INCCOM | 2,262,990 | $23.0M | 9.12% |
| 5 | ORCHARD THERAPEUTICS PLCSPON ADS NEW | 12,315,654 | $14.0M | 5.56% |
| 6 | LARIMAR THERAPEUTICS INCCOM | 3,414,468 | $13.5M | 5.35% |
| 7 | KEROS THERAPEUTICS INCCOM | 407,633 | $13.0M | 5.15% |
| 8 | IKENA ONCOLOGY INCCOM | 2,180,934 | $9.4M | 3.74% |
| 9 | ULTRAGENYX PHARMACEUTICAL INCOM | 215,000 | $7.7M | 3.04% |
| 10 | COMPASS THERAPEUTICS INCCOM | 2,829,712 | $5.6M | 2.21% |
18 more rows. Subscribe for $29/month to see every row, download the data and use the API.